Literature DB >> 16835499

BK virus and cancer in Uganda.

Robert Newton1, Tatiana Ribeiro, Eva Alvarez, John Ziegler, Delphine Casabonne, Lucy Carpenter, Valerie Beral, Edward Mbidde, Donald Maxwell Parkin, Henry Wabinga, Sam Mbulaiteye, Harold Jaffe, Antoine Touzé, Pierre Coursaget.   

Abstract

As part of an epidemiological study of cancer in Uganda, we investigated the titre of antibodies against BK virus among 821 people with different cancer types and benign tumours. Among study participants, 790 were considered seropositive for anti-BK virus antibodies and all analyses were conducted on transformed data. The mean optical density (a measure of antibody titre) for all patients combined (including the 31 who were considered seronegative) was 1.03 (standard error 0.01), but was 5% higher in women than in men (P=0.05), and 8% higher among HIV seropositive than seronegative people (P=0.002). Otherwise, there were few consistent associations between anti-BK virus antibodies and any social and lifestyle factor investigated. Differences in the mean optical density for each cancer type were estimated using multivariate analysis of variance with adjustment for sex, age group and HIV serostatus, using all other patients as controls. The mean optical density was about 17% lower among those with oral cancer (optical density 0.86, standard error 0.06; P=0.01, based on 30 patients) and about 20% higher among those with prostate cancer (optical density 1.22, standard error 0.09; P=0.01, based on 11 cases) than among all other patients combined. The number of cases of each cancer was too small to exclude the possibility of these findings arising by chance. No other cancer site or type was significantly associated with low, or with high anti-BK virus antibody titres.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835499     DOI: 10.1097/00008469-200608000-00002

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  4 in total

Review 1.  BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.

Authors:  George R Ambalathingal; Ross S Francis; Mark J Smyth; Corey Smith; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

Review 2.  BK virus and human cancer: innocent until proven guilty.

Authors:  Johanna R Abend; Mengxi Jiang; Michael J Imperiale
Journal:  Semin Cancer Biol       Date:  2009-02-21       Impact factor: 15.707

3.  Polyomavirus BK and prostate cancer: an unworthy scientific effort?

Authors:  Pasquale Ferrante; Maurizio Provenzano; Serena Delbue
Journal:  Oncoscience       Date:  2014-04-30

4.  Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort.

Authors:  R Newton; T Ribeiro; D Casabonne; E Alvarez; A Touzé; T Key; P Coursaget
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.